Eli Lilly wants to gain on Novo Nordisk's obesity lead
US-based Eli Lilly has recently released strong data for its obesity drug, and is now investigating options to get it onto the market sooner than expected.
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
While Novo Nordisk has taken the center stage of the obesity market in the US, the Danish pharmaceutical firm’s archrival there, Eli Lilly, is plotting ways to commercially challenge Wegovy with its own candidate, tirzepatide.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk remains coy over Wegovy blockbuster potential
For subscribers
Novo Nordisk upgrades full-year guidance
For subscribers
.jpg&w=384&q=75)
